Updated on 10 January 2013
ProMetic Life Sciences to get has $10 million strategic equity investment from Shenzhen Hepalink Pharma
Singapore: ProMetic Life Sciences has finalized the $10 million strategic equity investment by Shenzhen Hepalink Pharmaceutical pursuant to the terms and conditions previously disclosed on October 16, 2012.
Mr Pierre Laurin, president and CEO, ProMetic, said that, "The funds received will enable the execution of various strategic initiatives, including the 2013 operational launch of ProMetic's GMP plasma facility, located in Laval, Quebec in Canada, and dedicated to the manufacturing of plasma derived products."
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
